At the same time, inflammatory mediators, IL-1β, IL-18, and caspase-1 levels at SAT are significantly increased in patients with MetS compared to controls, which may contribute to an increase in insulin resistance, inflammation, and SAT fibrosis [120]. This evidence concerns the gene IL1B and metabolic syndrome.